Interest.co.nz With significant start-up costs, on-going research complications, the need for extensive clinical trials and the inevitable delays in getting products to market this is not a business for the faint hearted. While New Zealand's track record in the ... and more »
生物医药 再受关注精选八大概念股以供参考(附股) 股城网 编者按：大观霉素的生产商主要是鲁抗医药（行情,资金,股吧,问诊）.2012年4月，鲁抗医药的盐酸大观霉素顺利通过了美国FDA官方现场认证检查，至此先后获得了美国FDA和欧盟cGMP的认可，有望成为海外抗生素需求增加的受益 ... and more »
Seeking Alpha Shares of the world's largest provider of bio-pharmaceutical development services and commercial outsourcing services ended their first trading day with gains of 5.3% at $42.11 per share. This came after shares reached intra-day highs of $44 per share.
